FR17C1058I2 - Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids - Google Patents

Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids

Info

Publication number
FR17C1058I2
FR17C1058I2 FR17C1058C FR17C1058C FR17C1058I2 FR 17C1058 I2 FR17C1058 I2 FR 17C1058I2 FR 17C1058 C FR17C1058 C FR 17C1058C FR 17C1058 C FR17C1058 C FR 17C1058C FR 17C1058 I2 FR17C1058 I2 FR 17C1058I2
Authority
FR
France
Prior art keywords
bupropion
compositions
weight loss
opioid antagonist
influence weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C1058C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orexigen Therapeutics Inc
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04760321A external-priority patent/EP1617832B1/fr
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of FR17C1058I1 publication Critical patent/FR17C1058I1/fr
Application granted granted Critical
Publication of FR17C1058I2 publication Critical patent/FR17C1058I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR17C1058C 2003-04-29 2017-12-08 Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids Active FR17C1058I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46683803P 2003-04-29 2003-04-29
EP04760321A EP1617832B1 (fr) 2003-04-29 2004-04-21 Compositions influant sur la perte de poids
EP07116330A EP1870096A3 (fr) 2003-04-29 2004-04-21 Compositions pour influencer la perte de poids

Publications (2)

Publication Number Publication Date
FR17C1058I1 FR17C1058I1 (fr) 2018-01-12
FR17C1058I2 true FR17C1058I2 (fr) 2019-01-11

Family

ID=38719840

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1058C Active FR17C1058I2 (fr) 2003-04-29 2017-12-08 Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids

Country Status (6)

Country Link
EP (1) EP1870096A3 (fr)
BE (1) BE2017C064I2 (fr)
CY (2) CY1119418T1 (fr)
FR (1) FR17C1058I2 (fr)
LU (1) LUC00054I2 (fr)
NL (1) NL300918I2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012111011A2 (fr) 2011-02-16 2012-08-23 Nir Barak Associations faiblement dosées de fluoxétine et réboxétine pour traiter l'obésité
CA2899455C (fr) 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Traitement de la depression et autres maladies avec un agent a faible dose

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) * 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
ATE214276T1 (de) * 1994-09-19 2002-03-15 Du Pont Pharm Co Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
DE69736928T2 (de) * 1996-05-07 2007-06-28 Pliva Istrazivanje I Razvoj D.O.O. Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus
WO1999038504A1 (fr) * 1998-01-29 1999-08-05 Sepracor Inc. Utilisations pharmaceutiques de (-)-bupropion optiquement pur
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
WO2001052851A1 (fr) * 2000-01-22 2001-07-26 Albert Shulman Methodes de traitement d'abus de substances
EP1326630B1 (fr) * 2000-09-18 2008-05-28 Sanos Bioscience A/S Utilisation de peptides glp-2
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
AU2003242527B2 (en) * 2002-05-17 2008-10-23 Tioga Pharmaceuticals, Inc. Use of compounds that are effective as selective opiate receptor modulators
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake

Also Published As

Publication number Publication date
CY2017041I1 (el) 2018-09-05
NL300918I2 (nl) 2018-01-09
NL300918I1 (nl) 2017-12-14
CY1119418T1 (el) 2018-03-07
CY2017041I2 (el) 2018-09-05
EP1870096A2 (fr) 2007-12-26
BE2017C064I2 (fr) 2023-08-09
EP1870096A3 (fr) 2011-04-20
FR17C1058I1 (fr) 2018-01-12
LUC00054I2 (fr) 2018-02-21
LUC00054I1 (fr) 2017-12-13

Similar Documents

Publication Publication Date Title
LTC1694363I2 (lt) Monodispersinės pegiliuoto naloksolio kompozicijos
HK1103073A1 (en) Substituted diaza-spiro-[5.5-undecane derivatives and their use as neurokinin antagonists
IL179595A0 (en) Substituted indazoles, compositions containing same, preparation and use
EP1827389A4 (fr) Compositions a nanoparticules a liberation prolongee et procedes d'utilisation
IS8117A (is) 3-Flúr-píperidín sem NMDA/NR2B mótlyf
ZA200702131B (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof l
PL378244A1 (pl) Pirolilotiazole i ich zastosowanie jako odwrotnych agonistów receptora CB 1
ATE539138T1 (de) Schmierstoffzusammensetzungen
GB0326284D0 (en) Microbicidal compositions and their use
DE602004004278D1 (de) 4-cycloalkylaminopyrazolopyrimidin als nmda/nr2b-antagonisten
FR2836389B3 (fr) Poids pour appareil de musculation
EP1617872A4 (fr) Procedes et compositions permettant de renforcer une reponse immune
FR17C1058I2 (fr) Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids
FR2867275B1 (fr) Capteur de poids
GB2419373B (en) Improvements in or relating to an access platform
GB0327091D0 (en) Improvements in or relating to compositions
EP1670314A4 (fr) Procedes et compositions renfermant des diamines comme nouveaux produits therapeutiques antituberculeux
ITMI20031166A1 (it) Sedile per apparati di divertimento.
FR2865938B1 (fr) Formulation retard solide comprenant de l'acetate de triptoreline
PL1684715T3 (pl) Kompozycje zawierające nerameksan
IL157398A0 (en) Pharmaceutical compositions comprising ccr5 antagonists
GB0303675D0 (en) Improvements in or relating to flavour compositions
GB0322993D0 (en) Improvements in or relating to an access platform
GB0313682D0 (en) Cup trophy structure
GB0303676D0 (en) Improvements in or relating to flavour compositions